Kestra Medical CCO granted 25,227 RSUs

Ford Alfred J Jr reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ford Alfred J Jr reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies Chief Commercial Officer receives equity award. Alfred J. Ford Jr. was granted 25,227 restricted stock units, each representing one common share at settlement and awarded at no cash cost. Subject to continued service, the RSUs will vest over three years, with one-third vesting on each anniversary of June 3, 2026. After this grant, his reported direct holdings total 74,639 common shares or share-equivalent units.

Insider Trade Summary

Grant/Award: 25,227 shares

Grant/Award 1 txn

Insider Ford Alfred J Jr

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	25,227	$0.00	$0.00

Holdings After Transaction: Common Shares — 74,639 shares (Direct)

Footnotes (1)

F1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Key Figures

RSUs granted: 25,227 units Post-grant holdings: 74,639 shares Award price: $0.0000 per share

3 metrics

RSUs granted 25,227 units Restricted stock units awarded to Chief Commercial Officer

Post-grant holdings 74,639 shares Total direct holdings after RSU grant

Award price $0.0000 per share Grant, award, or other acquisition of RSUs

Key Terms

restricted stock units ("RSU"), vest over three years, anniversary of June 3, 2026, Chief Commercial Officer

4 terms

restricted stock units ("RSU") financial

"Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share"

vest over three years financial

"Subject to the Reporting Person's continued service, the RSUs will vest over three years"

anniversary of June 3, 2026 financial

"with 1/3 vesting on each anniversary of June 3, 2026"

Chief Commercial Officer financial

"officer_title": "Chief Commercial Officer"

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kestra Medical (KMTS) insider Alfred J. Ford Jr. report on this Form 4?

Alfred J. Ford Jr., Chief Commercial Officer of Kestra Medical Technologies, reported receiving 25,227 restricted stock units. These RSUs represent future rights to common shares as part of his equity compensation, rather than an open-market stock purchase.

How many Kestra Medical (KMTS) RSUs were granted to Alfred J. Ford Jr.?

He was granted 25,227 restricted stock units. Each RSU entitles him to receive one Kestra Medical common share at settlement, subject to vesting and continued service with the company over the defined vesting schedule.

What is the vesting schedule for Alfred J. Ford Jr.’s KMTS restricted stock units?

The RSUs will vest over three years, with one-third vesting on each anniversary of June 3, 2026. Vesting is conditioned on Alfred J. Ford Jr.’s continued service with Kestra Medical Technologies throughout this period.

What are Alfred J. Ford Jr.’s total reported Kestra Medical (KMTS) holdings after this grant?

Following the RSU grant, his total direct holdings are reported as 74,639 common shares or share-equivalent units. This figure reflects his position after the award recorded in this Form 4 filing for Kestra Medical Technologies.

Was cash paid for the Kestra Medical (KMTS) RSUs granted to Alfred J. Ford Jr.?

No cash was paid for these restricted stock units, which were granted at a reported price of $0.0000 per share. The award represents equity compensation that may convert into common shares as the RSUs vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/04/2026 - 06:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ford Alfred J Jr

(Last)

(First)

(Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND

WASHINGTON

98033

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/03/2026		A		25,227⁽¹⁾	A	$0	74,639	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

	/s/ Traci S. Umber as attorney-in-fact for Alfred J. Ford Jr.	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR